Canaccord ups Regeneron to buy, sees high-dose Eylea re-igniting sales
Kameleon007
Canaccord Genuity has raised its rating on Regeneron (NASDAQ:REGN) to buy, commenting that the FDAâs decision to approve a higher dose of the company's drug Eylea will help re-ignite sales and take back market share from Rocheâs (OTCQX:RHHBY) drug Vabysmo.
The investment bank said it believes high-dose Eylea is a superior product to Vabysmo, in part because it is less frequently dosed. It sees doctors and patients favoring high-dose Eylea, suggesting that the drug could regain its position as the dominant branded product during 2H 2023 and early 2024. 
Canaccord added that it views high-dose Eyleaâs price of $2,625 per vial as âappropriate for the drug's efficacy advantage vs Roche's Vabysmoâ and expects the product to launch immediately. 
Canaccord raised its price target for Regeneron to $992 from $720.

More on Regeneron Pharmaceuticals

Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade)

Regeneron Pharmaceuticals Inc. (REGN) Q2 2023 Earnings Call Transcript
Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening
Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront
Regeneron, J&J receive millions to develop new COVID therapies
With two approvals in one day, Regeneron could be headed higher
Regeneron high-dose Eylea gains FDA approval
Regeneron wins approval for rare immune disease therapy pozelimab
Seeking Alphaâs Quant Rating on Regeneron Pharmaceuticals
Earnings data for Regeneron Pharmaceuticals
Dividend for Regeneron Pharmaceuticals